Company / Operating Income
Kymera Therapeutics, Inc. Operating Income History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$349.4M
FY2025
5-year range
-$349.4M / -$42.2M
FY2021-FY2025
Trend
-33.5%
vs FY2024
Sector context
#171 of 204
Health Care
What the data says
Kymera Therapeutics, Inc.'s operating income of -$349M is lower than 84% of companies in the Health Care sector (FY2025). Operating Income has declined for 4 consecutive years, from -$42M in FY2021 to -$349M in FY2025.
Based on SEC 10-K filings.
-$349M in FY2025.
Declined from -$166M to -$349M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 204This company -$349.4M Sector average $107.8M
▼
-424.3% below sector average
Key checks
Key Insights
- Kymera Therapeutics, Inc.'s operating income has declined for 4 consecutive years.
- In FY2025, operating income decreased 33.5% year-over-year.
- Ranks #171 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$349.4M | -33.5% |
| FY2024 | -$261.6M | -58.1% |
| FY2023 | -$165.5M | -2.7% |
| FY2022 | -$161.3M | -282.1% |
| FY2021 | -$42.2M | +0.0% |
| FY2020 | -$42.2M | +0.0% |
| FY2019 | -$42.2M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026